Has Daniel Kiernan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,846,008 in general payments to Daniel Kiernan, MD across 1,500 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Daniel Kiernan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Daniel Kiernan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Daniel Kiernan, MD

Ophthalmology · Sarasota, FLNPI 1376790022

Payments from drug & device makers

$1,846,008in general payments, 2019–2025

Across 1,500 payments — averaging $1230.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron Healthcare Solutions, Inc.$513K
Mallinckrodt Hospital Products Inc.$422K
Eyepoint US, Inc.$241K
AbbVie$176K
Mallinckrodt Enterprises LLC$117K
Coherus Oncology, Inc.$82K
plus $295K from 34 others

$28,060in research payments, 2019–2025

Across 1 payment — averaging $28,060 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eyepoint US, Inc.$28K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron Healthcare Solutions, Inc.	388	$512,796
Mallinckrodt Hospital Products Inc.	224	$422,173
Eyepoint US, Inc.	145	$240,808
AbbVie(2 entities)	152	$176,360
Mallinckrodt Enterprises LLC	93	$116,754
Coherus Oncology, Inc.	60	$82,085
Alimera Sciences, Inc.	89	$78,921
Spark Therapeutics, Inc.	39	$69,228
Apellis Pharmaceuticals, Inc.	40	$30,993
Harrow Eye, LLC	12	$23,316
Novartis	51	$19,709
ANI Pharmaceuticals, Inc.	19	$15,800
Genentech USA, Inc.	31	$12,000
Bausch & Lomb Americas Inc.	34	$11,643
Regeneron	22	$11,479
Beaver-visitec International, Inc.	3	$10,152
Ocular Therapeutix, Inc.	7	$2,924
Heidelberg Engineering, Inc.	1	$1,700
Genentech, Inc.	7	$1,485
Alcon	17	$1,265
Notal Vision, Inc.	8	$1,164
Biogen	8	$495
Astellas Pharma US Inc	12	$461
Amgen	4	$291
Dutch Ophthalmic, USA	2	$254
LKC Technologies, Inc.	3	$237
Bausch & Lomb, A Division Of Bausch Health US, LLC	4	$203
Sight Sciences, Inc.	3	$183
Astellas Pharma Global Development	2	$160
Johnson & Johnson Surgical Vision, Inc.	1	$147
Oyster Point Pharma, Inc.	1	$125
Kala Pharmaceuticals, Inc.	1	$119
Shire North American Group Inc	5	$115
Johnson & Johnson	1	$104
Sun Pharmaceutical Industries Inc.	1	$93
Aerie Pharmaceuticals, Inc.	4	$81
Sandoz	2	$76
NEW World Medical,inc.	2	$63
Neurotech Pharmaceuticals, Inc.	1	$28
E.r. Squibb & Sons, L.L.C.	1	$22

How this compares

$1,846,008 in reported general payments places this provider in the 95th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024

$5,155,252

Medicare patients

980

Services billed

38,831

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other ophthalmology in Sarasota

Jody AbramsSarasota$515K
Robert SnyderSarasota$387K
David EichenbaumSt Petersburg$34.4M
Robert RadenDelray Beach$7.8M
Carl DanzigPompano Beach$5.3M
Bruce SegalDelray Beach$4.7M
Cathleen McCabeBradenton$4.6M
Ivan SunerTampa$3.7M
Sunir JoshiFt Lauderdale$3.7M
Harold BrooksTallahassee$3.5M

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →